Jazz Pharmaceuticals plc — Director's Dealing 2025

Nov 21, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-11-18

Reporting Person: Carr Patricia (SVP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-18	Ordinary Shares	S	69	$181.66	Disposed	7012	Direct
2025-11-18	Ordinary Shares	M	5250	$136.18	Acquired	12262	Direct
2025-11-18	Ordinary Shares	S	5250	$182.07	Disposed	7012	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-18	Non-Qualified Stock Option (right to buy)	$136.18	M	5250	Disposed	2027-03-01	Ordinary Shares (5250)	Direct

Footnotes

F1: The Reporting Person acquired 69 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025.

F2: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option was fully vested as of March 2, 2021.